EMA Authorised: Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) (chenodeoxycholic acid) — Leadiant Biosciences Ireland Limited

View source ↗

Summary

The EMA authorises chenodeoxycholic acid (Leadiant) for Xanthomatosis, Cerebrotendinous and Metabolism, Inborn Errors; designated as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolism Inborn Errors
• Xanthomatosis Cerebrotendinous

Drugs mentioned

• Chenodeoxycholic acid Leadiant (chenodeoxycholic acid)

Snippet

Status: Authorised. Therapeutic area: Xanthomatosis, Cerebrotendinous;Metabolism, Inborn Errors. MAH: Leadiant Biosciences Ireland Limited. Decision date: 12/08/2026. Orphan medicine